Metabotropic Glutamate Receptor 2 Antibody (C-term) Blocking peptide

Provided below are standard protocols that you may find useful for product applications.

Background

L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 and these receptors have been shown to activate phospholipase C. Group II includes GRM2 (also known as GPRC1B) and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. The activity of GRM2 is mediated by a G-protein that inhibits adenylate cyclase activity. This protein may mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.

References

Anneser, J.M., et al., J. Neuropathol. Exp. Neurol. 63(8):831-840 (2004).Dietrich, D., et al., Neuropharmacology 42(3):297-305 (2002).Krampfl, K., et al., Eur. J. Neurosci. 15(1):51-62 (2002).Marti, S.B., et al., Am. J. Med. Genet. 114(1):12-14 (2002).Malherbe, P., et al., Mol. Pharmacol. 60(5):944-954 (2001).